BG108180A - Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases - Google Patents

Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Info

Publication number
BG108180A
BG108180A BG108180A BG10818003A BG108180A BG 108180 A BG108180 A BG 108180A BG 108180 A BG108180 A BG 108180A BG 10818003 A BG10818003 A BG 10818003A BG 108180 A BG108180 A BG 108180A
Authority
BG
Bulgaria
Prior art keywords
treat diseases
compounds
formula
dihydropyrimidine compounds
substituted dihydropyrimidine
Prior art date
Application number
BG108180A
Other languages
Bulgarian (bg)
English (en)
Inventor
Spencer D. Kimball
Louis J. Lombardo
David B. Rawlins
Hai-Yun Xiao
Robert J. Schmidt
David K. Williams
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG108180A publication Critical patent/BG108180A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG108180A 2001-03-29 2003-09-17 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases BG108180A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29
PCT/US2002/009497 WO2002079149A2 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Publications (1)

Publication Number Publication Date
BG108180A true BG108180A (en) 2004-09-30

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108180A BG108180A (en) 2001-03-29 2003-09-17 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Country Status (26)

Country Link
US (1) US6809102B2 (enExample)
EP (1) EP1373221A4 (enExample)
JP (1) JP2005504725A (enExample)
KR (1) KR20030086327A (enExample)
CN (1) CN1507435A (enExample)
AR (1) AR034585A1 (enExample)
BG (1) BG108180A (enExample)
BR (1) BR0208405A (enExample)
CA (1) CA2442482A1 (enExample)
CZ (1) CZ20032645A3 (enExample)
EE (1) EE200300474A (enExample)
HR (1) HRP20030875A2 (enExample)
HU (1) HUP0400350A3 (enExample)
IL (1) IL157441A0 (enExample)
IS (1) IS6967A (enExample)
MX (1) MXPA03008634A (enExample)
NO (1) NO20034300L (enExample)
PE (1) PE20021013A1 (enExample)
PL (1) PL373759A1 (enExample)
RU (1) RU2003130961A (enExample)
SK (1) SK11062003A3 (enExample)
TW (1) TWI228416B (enExample)
UY (1) UY27232A1 (enExample)
WO (1) WO2002079149A2 (enExample)
YU (1) YU75803A (enExample)
ZA (2) ZA200306648B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
PT1847534E (pt) * 2001-12-11 2011-08-01 Kyowa Hakko Kirin Co Ltd Derivado de tiadiozolina para o tratamento do cancro
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
WO2004092147A1 (ja) 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. M期キネシン阻害剤
CN1802361A (zh) * 2003-06-10 2006-07-12 协和发酵工业株式会社 噻二唑啉衍生物
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US20050282838A1 (en) * 2003-10-16 2005-12-22 Shyamlal Ramchandani Compounds, compositions, and methods
UA84954C2 (ru) * 2004-07-22 2008-12-10 Astrazeneca Ab Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
AU2005273705B8 (en) * 2004-08-18 2010-01-28 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
CN101193877A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 造血系统肿瘤治疗剂
EP1867640A4 (en) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd MEANS FOR TREATING SOLID TUMORS
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
CA2205384C (en) 1994-11-16 2004-06-29 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
AU727972B2 (en) 1996-05-16 2001-01-04 H. Lundbeck A/S Dihydropyrimidines and uses thereof
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
WO1998057639A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
EP1066527A2 (en) 1998-04-01 2001-01-10 Yale University Method to identify modulators of survivin - tubulin interaction
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
AR034585A1 (es) 2004-03-03
HUP0400350A2 (hu) 2005-01-28
HUP0400350A3 (en) 2005-06-28
US6809102B2 (en) 2004-10-26
KR20030086327A (ko) 2003-11-07
WO2002079149A3 (en) 2003-02-27
SK11062003A3 (sk) 2004-08-03
ZA200307320B (en) 2004-12-20
IS6967A (is) 2003-09-24
NO20034300L (no) 2003-11-07
YU75803A (sh) 2006-05-25
NO20034300D0 (no) 2003-09-26
WO2002079149A2 (en) 2002-10-10
IL157441A0 (en) 2004-03-28
PL373759A1 (en) 2005-09-05
EE200300474A (et) 2003-12-15
JP2005504725A (ja) 2005-02-17
CA2442482A1 (en) 2002-10-10
EP1373221A2 (en) 2004-01-02
RU2003130961A (ru) 2005-04-10
CZ20032645A3 (cs) 2004-06-16
TWI228416B (en) 2005-03-01
PE20021013A1 (es) 2002-11-10
BR0208405A (pt) 2004-03-30
MXPA03008634A (es) 2003-12-08
HRP20030875A2 (en) 2004-08-31
ZA200306648B (en) 2004-11-26
EP1373221A4 (en) 2004-09-29
UY27232A1 (es) 2002-11-29
US20030008888A1 (en) 2003-01-09
CN1507435A (zh) 2004-06-23

Similar Documents

Publication Publication Date Title
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
TW200504034A (en) Therapeutic agents
TW200531689A (en) Therapeutic agents
TW200635903A (en) Therapeutic agents
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
WO2004106492A3 (en) Bicyclicpyrimidones and their use to treat diseases
YU84603A (sh) Novi inhibitori tirozin kinaze
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
TNSN06228A1 (en) Compounds and methods of use
AU8490901A (en) Urea compounds and methods of uses
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
TW200503710A (en) Novel compounds
TW200633986A (en) Therapeutic agents
TW200509933A (en) Therapeutic agents
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
IL157457A0 (en) Benzimidazoles that are useful in treating sexual dysfuction
PL1725536T3 (pl) Pochodne imidazoliny mające czynność CB1-antagonistyczną
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF